Shell Asset Management CO Neurocrine Biosciences Inc Transaction History
Shell Asset Management CO
- $2.27 Billion
- Q3 2024
A detailed history of Shell Asset Management CO transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Shell Asset Management CO holds 6,240 shares of NBIX stock, worth $780,000. This represents 0.03% of its overall portfolio holdings.
Number of Shares
6,240
Previous 6,429
2.94%
Holding current value
$780,000
Previous $885,000
18.76%
% of portfolio
0.03%
Previous 0.04%
Shares
28 transactions
Others Institutions Holding NBIX
# of Institutions
625Shares Held
94.2MCall Options Held
632KPut Options Held
621K-
Black Rock Inc. New York, NY14.2MShares$1.77 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA10MShares$1.25 Billion0.02% of portfolio
-
State Street Corp Boston, MA5.15MShares$644 Million0.02% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.57MShares$322 Million0.47% of portfolio
-
Bellevue Group Ag Kuesnacht, V81.86MShares$233 Million3.62% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $12B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...